AGN 197075

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: AGN 197075
• 英文别名: 1-(3-chloro-2-fluorobenzyl)-3-(2-hydroxyethyl)-thiourea；1-[(3-Chloro-2-fluorophenyl)methyl]-3-(2-hydroxyethyl)thiourea
• 化学式: C₁₀H₁₂ClFN₂OS
• 分子量: 262.735
• InChiKey: OSYJXTFJYWBYCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  76.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-Chloro-2-fluorobenzyl isothiocyanate 、 C.I.酸性橙108 以 乙腈 为溶剂， 反应 14.0h， 生成 AGN 197075
  参考文献：
  名称：

  [EN] COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN
  [FR] NOUVEAUX PROCEDES ET NOUVELLES COMPOSITIONS DESTINEES A SOULAGER LA DOULEUR

  摘要：

  公开号：

  WO2003099289A3

文献信息

• Methods and compositions for modulating alpha adrenergic receptor activity
  申请人：ALLERGAN SALES, INC.

  公开号：US20020058839A1

  公开（公告）日：2002-05-16

  Methods and compositions for the treatment of pain. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.

  治疗疼痛的方法和组合物。特别披露了用于治疗慢性疼痛的新组合物，以及它们的使用方法。
• METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY
  申请人：Chow Ken

  公开号：US20080132576A1

  公开（公告）日：2008-06-05

  Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.

  治疗疼痛和眼内压的方法和组合物。特别是揭示了用于治疗慢性疼痛、青光眼的新组合物以及其使用方法。
• Novel methods and compositions for alleviating pain
  申请人：Allergan, Inc.

  公开号：EP2351561A2

  公开（公告）日：2011-08-03

  The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic alpha-adrenergic receptor in the absence of alpha-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic alpha-adrenergic receptor can be, for example, the alpha-2B receptor.

  本发明提供了一种长期缓解受试者慢性疼痛的方法，在α-2A受体未被激活的情况下，激活受试者体内的镇痛剂α-肾上腺素能受体至少三天，从而在所述受体未被持续激活的情况下保持慢性疼痛的缓解。镇痛的α-肾上腺素能受体可以是α-2B受体等。
• Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists
  申请人：Allergan, Inc.

  公开号：US10251865B2

  公开（公告）日：2019-04-09

  Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.

  本文公开了一种通过施用α-2 受体激动剂来上调调节性 T 细胞并治疗可从这种上调中获益的疾病的方法。
• Treatment of autism spectrum disorder and associated symptoms
  申请人：Price Richard Louis

  公开号：US10688179B2

  公开（公告）日：2020-06-23

  Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

  本发明公开了一种单件口服剂型，该剂型结合了肌醇和缓释氯尼地定或缓释胍法辛。在一个方面，治疗多动症和/或相关症状的方法包括向多动症患者施用单一口服剂型。在另一方面，治疗多动症和/或其相关症状的方法包括向多动症患者施用肌醇与缓释氯尼丁或缓释胍法辛的组合，无论是单独施用还是作为单一剂型施用。